Uncovering a hidden and potentially fatal disease that one in four of us have without knowing it.

We are introducing data driven diagnostics to ensure timely detection of chronic liver disease.

Say hello to evido.

We are a collective of hepatologists, clinical researchers, data geeks, venture builders and healthcare innovators.

All with a common goal to help people that are living with a hidden and potentially fatal chronic liver disease.

Most people have never heard of Fatty Liver Disease.

Despite the fact that:
· it is a global health challenge
· one in four of us have it and
· it kills more than one million people every year.

Fatty Liver Disease is a hidden disease where three out of four are undiagnosed until it is too late.

Our mission is to ensure timely detection and support to people living with chronic liver disease.

Through extensive clinical research, we have identified new ways to use already available data to empower patients and healthcare personnel. Thereby bridging a crucial gap in current healthcare practices.

Our mission is to ensure timely detection and support to people living with chronic liver disease.

Through extensive clinical research, we have identified new ways to use already available data to empower patients and healthcare personnel. Thereby bridging a crucial gap in current healthcare practices.

We will soon release our first solutions. Reach out to get a demo or early access.

01 Primary care

Data-driven risk stratification of at-risk people.

Enabling timely detection of at-risk people at the first point of contact with the person.

Book a demo

02 Secondary care

Automated assessment of liver-referrals at specialised clinics.

Automated liver-referral assessment at specialised clinics to remove redundant referrals and optimise the use of healthcare specialists.

Book a demo

Say hello to evido.

evido.health is a collective of hepatologist, clinical researchers, data geeks, venture builders and healthcare innovators.
‍
‍All with a common goal to help people at risk of Chronic Liver Disease by re-inventing diagnostics and care with evidence-based and data-driven solutions.

001

002

003

Fighting a global health challenge

Imagine getting the news that you may die soon from a Chronic Liver Disease you’ve had for years without knowing it.
‍
Few of us have heard of Fatty Liver Disease.
One in four of us have it.
It kills more than one million people every year.

Fatty Liver Disease is a hidden and chronic liver disease that can progress to a fatal stage without you feeling any symptoms. In fact, three out of four people that die from it are unaware their liver is sick before it is too late.

001

002

003

Our mission

Our mission is to ensure timely detection and support to people living with Chronic Liver Disease with data-driven solutions.

We are introducing data-driven solutions to close a crucial gap in the field of Chronic Liver Disease.

001

002

003

Say hello to evido.

001

002

003

Fighting a global health challenge

001

002

003

Our mission

001

002

003

Value creation

We help people with chronic liver disease at the right time.

Our evidence-based software can detect at-risk people of chronic liver disease at the right time - harvesting benefits for both people with chronic liver disease, healthcare professionals and the healthcare system. We are compatible with existing healthcare information systems and are currently establishing pilots in several health clinics in the Nordics.

Here are 4 key benefits of our solutions.

Our solutions allow for timely detection of people that unknowingly walk around with a progressing and potentially fatal liver disease. This enables us to initiate treatment before it is too late and thereby saving the lives of those who otherwise would have progressed to a fatal stage.

Our solutions fill a gap in the field of liver diagnostics. We provide high accuracy risk stratification to large low-prevalent populations without over-diagnosing. Something that is not possible today.

Our risk stratification is based on standard and routine blood sample results. This allows us to offer an affordable and accurate solution for detecting at-risk people outside of the hospitals.

Optimising the patient pathway has a ripple effect on the entire value chain. We remove redundant liver referrals that currently represent more than 50% of all liver-related referrals to secondary care.

In turn, overstretched specialised healthcare professionals can focus on those people that benefit most from their expertise.

We provide specialised clinical recommendations at the first point of contact with at-risk people. This allows non-specialist clinicians to provide high quality care for both low, moderate and high-risk individuals.
‍
By empowering clinicians with actionable insights, we optimise the patient pathway and reduce costs across the healthcare system.

001

Timely detection of a potentially fatal disease.

Our datamodels allow for timely detection of people that unknowingly walk around with a progressing and potentially fatal liver disease. This enables us to initiate treatment before it is too late and thereby saving the lives of those who otherwise would have progressed to a fatal stage.

002

Efficient risk stratification for the masses.

003

Effective use of healthcare specialists.

004

Provision of specialised liver knowledge beyond hospitals.

Facts about Fatty Liver Disease

We are fighting a growing and global health challenge that is referred to as ‘the new diabetes’.

million

annual deaths caused by Fatty Liver Disease. That is on par with diabetes, tuberculosis and AIDS. It is outpacing most cancer forms.

leading cause of lost work-years in Europe.

of the western world population has Fatty Liver Disease.

of people who die from Fatty Liver Disease are unaware they are sick before it is too late.

of people diagnosed with end-stage Fatty Liver Disease die within 5 years.

More facts about Fatty Liver Disease

evido.health is founded and anchored in state of the art clinical research.

We have to keep pushing the boundaries of what is possible, and move away from the status quo. Through extensive clinical research of high scientific quality, we have discovered new ways to use already available data to make decision tools that will empower patients and healthcare personnel. Thereby we can bridge a crucial gap in current healthcare.

Maja Thiele, MD, Ph.d.

Professor of Hepatology at Center for Liver Research (OUH) and Board member of ‘Alkohol & Samfund'.

Scientific Cofounder of evido.health

Meet the team

evido.health is founded and anchored in state of the art clinical research.

Taus Holtug

Meet the team

evido.health is founded and anchored in state of the art clinical research.

Jens Kristian Damsgaard

Meet the team

evido.health is founded and anchored in state of the art clinical research.

Accessible and accurate diagnostic methods for early detection of high-risk patients is a cornerstone in battling the severe and global health challenge that Fatty Liver Disease poses.

Aleksander Krag, MD, Ph.d., MBA

Professor of Hepatology, Director at Center for Liver Research (OUH) and Vice President of EASL .

Scientific Cofounder of evido.heath

Meet the team

evido.health is founded and anchored in state of the art clinical research.

Jan Ankjær Jensen

Meet the team

evido.health is founded and anchored in state of the art clinical research.

I've met too many un-diagnosed patients coming in with end-stage Fatty Liver Disease. All we can do is to ease their condition by treating their complications. This is not sufficient. We need to take action and ensure timely support to these people before it is too late.

Katrine Prier Lindvig, MD

Experienced researcher in Hepatology.

Cofounder and Chief Scientific Officer in evido.health

Meet the team

evido. is founded and anchored in state of the art clinical research.

Maja Thiele, MD, Ph.d.

Professor of Hepatology at Center for Liver Research (OUH) and Board member of ‘Alkohol & Samfund'.

Scientific Cofounder of evido.health

Meet the team

Accessible and accurate diagnostic methods for early detection of high-risk patients is a cornerstone in battling the severe and global health challenge that Fatty Liver Disease poses.

Aleksander Krag, MD, Ph.d., MBA

Professor of Hepatology, Director at Center for Liver Research (OUH) and Vice President of EASL .

Scientific Cofounder of evido.heath

Meet the team

Katrine Prier Lindvig, MD

Experienced researcher in Hepatology.

Cofounder and Chief Scientific Officer in evido.health

Meet the team

ClinIcal validated technology and need.

Our technology is built on more than a decade of elite liver research and thousands of high quality patient data. We have experienced the pains of both patients, their families and clinicians first-hand.

It is what allow state-of-the-art performance to our solutions while creating real impact for both people at-risk and clinicians .

We design for disease prevention.

Early detection gives people a chance to change course. Our solutions target at-risk people before it is too late and provide clinicians with assessment and insights to support them. We’re changing the paradigm towards prevention rather then treating complications when it is too late to save lives.

We make data actionable and accessible.

Data is the key to unlock timely detection of high-risk people of Chronic Liver Disease. However data is only valuable if it is accessible and interpretable for the users. That is why, we provide our users with actionable data insights and specific clinical recommendation that fit their workflow. We give access to specialised liver knowledge where it is not present today and ensure that at-risk people get the proper care.

We piggyback on what works to ease adoption and scalability.

Our solutions are directly compatible with existing healthcare information systems and test practice. This is key to ease the adoption, avoid extensive training session that will never stick and ensure value creation from day 1.

Placing our software on top of the exisiting test infrastructure means that we instantly get access to exisitng at-risk people ‘funnels’ and can ensure timely detection during existing touchpoints with the healtcare system.

This ensures scalability and accelerates our time to impact.